Asymmetrex Discusses a Near Horizon for Stem Cell Dosage in Stem Cell Therapy and Gene Therapy Clinical Trial Supply Chains
Share Article
Today, May 11, in the Clinical Trial Supply USA 2021 – Virtual Conference, the President and CEO of stem cell biotechnology company Asymmetrex, James L. Sherley, M.D., Ph.D., discussed new developments on the horizon for the supply chains for stem cell therapy and gene therapy clinical trials. In particular, he suggested that it is inevitable that regulatory agencies like the FDA and clinical trial sponsors will eventually require stem cell dosage data for all supply chain activities, as well as for stem cell treatments.
Modernaâs CEO says he âdidnât lose a minute of sleepâ over potential waiver of vaccine patents
By Jonathan Saltzman Globe Staff,Updated May 6, 2021, 8:39 p.m.
Email to a Friend
Modernaâs production and lab facility in Norwood is doubling in size.John Tlumacki/Globe Staff
Moderna chief executive Stephane Bancel on Thursday shrugged off the Biden administrationâs support for suspending patents for coronavirus vaccines, saying drug firms in other countries would struggle to mass-produce a rival to the blockbuster vaccine that has made his company a household name.
Speaking during a first-quarter earnings call, the head of the Cambridge biotech said he âdidnât lose a minute of sleepâ after the administration said it would endorse the temporary waiver of patents to bolster vaccine production in developing nations
Asymmetrex Will Discuss the Impact of Its Technology for Dosing Therapeutic Stem Cells
Share Article
During the coming months of May and June, stem cell biotechnology company Asymmetrex is invited to give presentations in several different virtual conferences that span the fields of clinical trial supply, cell biotherapeutics, stem cell science, and stem cell medicine. The company’s relevance to these diverse disciplines reflects the broad scope of the impact of its emerging technologies for determining the dosage of therapeutic stem cells.
Asymmetrex President & CEO
James L. Sherley, M.D., Ph.D.
It’s basic medicine. Finally knowing the stem cell dosage of stem cell treatments must necessarily be better for patients.
Share this article
CAMBRIDGE, Mass., May 4, 2021 /PRNewswire/
Theseus Pharmaceuticals, a biotechnology company shaping the future of targeted oncology by developing best-in-class, pan-variant kinase inhibitors, today announced the appointment of Tim Clackson, Ph.D., as Chief Executive Officer and as a member of the Company s Board of Directors. He succeeds interim CEO Iain Dukes, D.Phil., Theseus Co-Founder and OrbiMed Venture Partner, who will serve as Theseus Executive Chairman. I am thrilled to join the team of R&D leaders at Theseus, who have a proven track record and share my passion for oncology innovation, motivated by our direct experience helping change patients lives with targeted therapies, said Dr. Clackson. Collectively, we are leveraging decades of insight to develop innovative medicines to confront the scourge of treatment resistance. With the backing of our top-tier investors, I look forward to realizing Theseus vision to build an industry leading precisi